- Conditions
- AMD - Age-Related Macular Degeneration, Diabetic Macular Edema
- Interventions
- Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)
- Device
- Lead sponsor
- Notal Vision Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 1,616
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Retinopathy
- Interventions
- Color fundus photography, Mydriatic Agent
- Procedure · Drug
- Lead sponsor
- Eyenuk, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Diabetic Retinopathy
- Interventions
- doxycycline monohydrate, Placebo
- Drug
- Lead sponsor
- Thomas Gardner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Macular Edema Secondary to Central Retinal Vein Occlusion
- Interventions
- VEGF Trap-Eye 2.0mg, Sham
- Biological · Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more
- Conditions
- Macular Edema
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Paducah, Kentucky • Charlotte, North Carolina • Chattanooga, Tennessee + 1 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- DE-120, Aflibercept
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Bakersfield, California • Walnut Creek, California + 11 more
- Conditions
- Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa (RP)
- Interventions
- No treatment: retrospective chart review
- Other
- Lead sponsor
- QLT Inc.
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Portland, Oregon
- Conditions
- Choroideremia, CHM (Choroideremia) Gene Mutations
- Interventions
- AAV2-hCHM
- Biological
- Lead sponsor
- Spark Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- Fluocinolone Acetonide
- Drug
- Lead sponsor
- Alimera Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 3
- States / cities
- Lexington, Kentucky • Boston, Massachusetts • Cleveland, Ohio
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment
- Interventions
- Optical Coherence Tomography Angiography (OCTA) Imaging, Noninvasive Retinal Amyloid Imaging (NRAI)
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Intervention, Usual Care
- Behavioral
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 21 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Bennettsville, South Carolina
- Conditions
- Wet Age Related Macular Degeneration, Wet AMD
- Interventions
- NT-101 Low Dose, NT-101 High Dose
- Drug
- Lead sponsor
- NexThera Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Rosedale, Maryland • Durham, North Carolina • Erie, Pennsylvania + 1 more
- Conditions
- Advanced Retinitis Pigmentosa
- Interventions
- AGN-151597
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 4
- States / cities
- San Francisco, California • Edgewood, Kentucky • Durham, North Carolina + 1 more
- Conditions
- Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Anterior, Panuveitis, Uveitis, Intermediate
- Interventions
- 4 mg CLS-TA, 0.8 mg CLS-TA
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 11
- States / cities
- Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Age Related Macular Degeneration
- Interventions
- carbidopa-levodopa
- Drug
- Lead sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
- Individual
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 2.0 mg OPT-302, 2.0 aflibercept, Sham
- Biological · Procedure
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 998 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 57 more
- Conditions
- Diabetic Retinopathy
- Interventions
- RETeval
- Device
- Lead sponsor
- Inoveon Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Decatur, Georgia • Oklahoma City, Oklahoma
- Conditions
- Hypoxic-Ischemic Encephalopathy
- Interventions
- Optical Coherence Tomography
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- Up to 20 Days
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Salt Lake City, Utah
- Conditions
- Macular Degeneration
- Interventions
- Pazopanib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Beverly Hills, California • Pasadena, California + 13 more
- Conditions
- Retinal Detachment
- Interventions
- Dextenza, Prednisolone Acetate
- Drug
- Lead sponsor
- Midwest Eye Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- Other: Assessments
- Other
- Lead sponsor
- NightstaRx Ltd, a Biogen Company
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more
- Conditions
- Retinal Vein Occlusion, Macular Edema
- Interventions
- Intravitreal injection of bevacizumab, Intravitreal injection of ranibizumab (0.5 mg per dose)
- Drug
- Lead sponsor
- Barnes Retina Institute
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Geographic Atrophy
- Interventions
- RNA-144101
- Drug
- Lead sponsor
- Mark Kleinman
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Diabetes, Diabetic Retinopathy
- Interventions
- DVS supplementation
- Dietary Supplement
- Lead sponsor
- ZeaVision, LLC
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Pomona, California • Tahlequah, Oklahoma